BHCM
MLTX icon

Boulder Hill Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Boulder Hill Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,500
Closed -$310K – 143
2023
Q1 		$310K Buy
+14,500
New +$244K 0.25% 86

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Boulder Hill Capital Management's MLTX Position: Q2 2023 in Review

Boulder Hill Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2023, closing a stake of 14,500 shares — an estimated $310K sold.

Boulder Hill Capital Management first reported a position in MLTX in Q1 2023 and held it in 1 quarter. The position peaked at $310K in Q1 2023. 83 funds tracked by Wall St. Rank hold MLTX as of Q2 2023.

  • Boulder Hill Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Boulder Hill Capital Management sold 14,500 MoonLake Immunotherapeutics shares in Q2 2023, an estimated $310K.
  • Boulder Hill Capital Management first reported a position in MoonLake Immunotherapeutics in Q1 2023 and held it in 1 quarter.
  • Boulder Hill Capital Management's MoonLake Immunotherapeutics position peaked at $310K in Q1 2023.
  • 83 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2023.

Based on Boulder Hill Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.